Merck Wants to Do More Multi Tens of Billion-Dollar Deals

Jan. 13, 2026, 1:24 AM UTC

Merck & Co. wants to strike more deals, seeing an opportunity for “multi tens of billion”-dollar acquisitions.

“We are not limited from a balance sheet — it’s more where do we see strategic opportunity,” Chief Executive Officer Rob Davis said at the JPMorgan Healthcare Conference in San Francisco.

The comments come amid speculation that Merck is in talks to buy cancer drugmaker Revolution Medicines Inc. The Financial Times reported last week, citing a person familiar, that the price tag being discussed was between $28 billion and $32 billion.

Merck is seeking deals to expand its portfolio of treatments as it ...

Learn more about Bloomberg Law or Log In to keep reading:

See Breaking News in Context

Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.

Already a subscriber?

Log in to keep reading or access research tools and resources.